Get the Stockscreener App
0.45
1.10%
-0.005
After Hours:
.43
-0.02
-4.44%
Pasithea Therapeutics Corp stock is traded at $0.45, with a volume of 357.23K.
It is down -1.10% in the last 24 hours and down -16.28% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
See More
Previous Close:
$0.455
Open:
$0.4677
24h Volume:
357.23K
Relative Volume:
0.47
Market Cap:
$15.04M
Revenue:
-
Net Income/Loss:
$-19.73M
P/E Ratio:
-0.217
EPS:
-2.0742
Net Cash Flow:
$-16.94M
1W Performance:
-4.90%
1M Performance:
-16.28%
6M Performance:
-46.85%
1Y Performance:
-38.02%
1-Day Range:
$0.45
$0.4948
1-Week Range:
$0.44
$0.50
52-Week Range:
$0.281
$2.06
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.45 | 15.20M | 0 | -19.73M | -16.94M | -2.0742 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Pasithea Therapeutics Corp (KTTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pasithea Therapeutics Corp (KTTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pasithea Therapeutics Corp (KTTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pasithea Therapeutics Corp. Revenue Breakdown – NASDAQ:KTTA - TradingView
KTTA|Pasithea Therapeutics Corp|Price:0.455|Chg%:-0.025 - TradingKey
Pasithea Therapeutics Corp. (KTTA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pasithea Therapeutics Corp. (KTTA) stock price, news, quote and history - Yahoo Finance UK
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology Congress 2026 - Investing News Network
Pasithea Therapeutics (KTTA) Registration filing Summary - Quartr
Pasithea Therapeutics (KTTA) Proxy filing Summary - Quartr
Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors - Quiver Quantitative
Pasithea's PAS-004 Study of Advanced Solid Tumors Gets ESMO Poster Slot - Stock Titan
New Strong Buy Stocks for July 20th - Yahoo Finance
Kartik Krishnan Net Worth (2026) - GuruFocus
Pasithea Therapeutics to present at B. Riley Mi... - Pluang
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - GlobeNewswire
KTTA Q1 2026 Earnings: Shares Surge on Better-Than-Expected Loss and Operational ProgressRevenue Growth Outlook - dars.gov.et
Pasithea Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock SurgeTax Rate Impact - dars.gov.et
Pasithea Therapeutics (KTTA) Tests Support After 1.99% DipGap Down Bounce Plays - Bölüm Sonu Canavarı
Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan
Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView
Pasithea extends dose escalation for MEK inhibitor PAS-004 - Investing.com UK
Pasithea extends dose escalation for MEK inhibitor PAS-004 By Investing.com - Investing.com South Africa
Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies. - Bitget
Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView
Price to book forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView
Pasithea Therapeutics Company Profile & Introduction - Moomoo
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Price to earnings forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Price to sales forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Pasithea Therapeutics Corp. Actuals & Estimates (NASDAQ:KTTA) - TradingView
KTTA Forecast — Price Target — Prediction for 2027 - TradingView
Pasithea Therapeutics Corp. Financial Disclosures & SEC Filings - TradingView
Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com - Investing.com South Africa
Stonepine Group reports 5.8% stake in Pasithea Therapeutics (KTTA) - Stock Titan
Major Investor Quietly Boosts Stake in Pasithea Therapeutics - TipRanks
Coastlands Capital LP acquires $53,000 of Pasithea stock - Investing.com UK
Coastlands Capital LP acquires $53,000 of Pasithea stock By Investing.com - Investing.com Australia
Form 4 Pasithea Therapeutics Corp For: 22 June By Investing.com - Investing.com Nigeria
Coastlands Capital LP (KTTA) adds 100,000 Pasithea Therapeutics shares in open-market buy - Stock Titan
Pasithea Therapeutics Corp (KTTA) Institutional Confidence - TradingKey
Pasithea Therapeutics Corp (KTTA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pasithea Therapeutics Corp (KTTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pasithea Therapeutics Corp (KTTAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pasithea Therapeutics Corp (KTTAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):